GSK plc (GSK) Thursday announced that it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to Bharat Biotech International Limited (BBIL).
As the vaccine candidate uses low-cost and scalable GMMA technology (Generalized Modules for Membrane Antigens), it is ideal for low-income countries, where Shigella, the leading bacterial cause of diarrhoea, poses a serious health threat to children under five years of age.
The interim statistical analysis conducted to date from the Phase 2 studies and the Phase I study of altSonflex1-2-3 had achieved pre-specified immunogenicity success criteria.
Following the technology transfer, GSK will work with BBIL on the design of the Phase 3 study and support BBIL's efforts to secure external funding. This partnership builds on GSK's existing relationship with Bharat Biotech, following a product transfer and licensing agreement in 2021 for the world's first malaria vaccine, RTS,S.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.